Effect of pomegranate seed oil on hyperlipidaemic subjects: a double-blind placebo-controlled clinical trial

Randomized Controlled Trial

doi: 10.1017/S0007114510000504. Epub 2010 Mar 25.

Affiliations

PMID: 20334708
DOI: 10.1017/S0007114510000504

Randomized Controlled Trial

Parvin Mirmiran et al. Br J Nutr. 2010 Aug.

Abstract

In vitro and in vivo studies have shown that punicic acid, a type of conjugated fatty acid and the main constituent of pomegranate seed oil (PSO), has anti-atherogenic effects. The present study aimed at determining the effect of PSO treatment on serum lipid profiles. This double-blind placebo-controlled randomised clinical trial included fifty-one hyperlipidaemic subjects, diagnosed according to National Cholesterol Education Program definition, and randomly assigned to the PSO and the control groups. The PSO and placebo groups received 400 mg PSO and placebo twice daily, respectively and were followed up for 4 weeks. Serum concentrations of lipids and lipoproteins were measured before and 4 weeks after intervention. Mean concentration of TAG and the TAG:HDL cholesterol (HDL-C) ratio were significantly decreased after 4 weeks in the PSO group as compared with baseline values (2.75 (sd 1.40) v. 3.45 (sd 1.56) mmol/l, P = 0.009 and 5.7 (sd 4.6) v. 7.5 (sd 5.0), P = 0.031, respectively). The treatment effect was statistically significant in the PSO group as compared with controls in diminution of cholesterol:HDL-C ratio (5.4 (sd 1.5) v. 5.9 (sd 1.4), P < 0.05) adjusted for baseline values. We found a mean difference for PSO v. placebo in HDL-C concentration (0.13 v. - 0.02 mmol/l) and cholesterol:HDL-C ratio ( - 0.42 v. 0.01, P < 0.05). Serum cholesterol, LDL cholesterol and glucose concentrations and body composition variables remained unchanged. It is concluded that administration of PSO for 4 weeks in hyperlipidaemic subjects had favourable effects on lipid profiles including TAG and TAG:HDL-C ratio.

PubMed Disclaimer

Cited by

Pomegranate variety and pomegranate plant part, relevance from bioactive point of view: a review.
Melgarejo-Sánchez P, Núñez-Gómez D, Martínez-Nicolás JJ, Hernández F, Legua P, Melgarejo P. Melgarejo-Sánchez P, et al. Bioresour Bioprocess. 2021 Jan 3;8(1):2. doi: 10.1186/s40643-020-00351-5. Bioresour Bioprocess. 2021. PMID: 38650225 Free PMC article. Review.
Effects of pomegranate seed oil on insulin release in rats with type 2 diabetes.
Nekooeian AA, Eftekhari MH, Adibi S, Rajaeifard A. Nekooeian AA, et al. Iran J Med Sci. 2014 Mar;39(2):130-5. Iran J Med Sci. 2014. PMID: 24644382 Free PMC article.
Suppression of tumor growth and apoptosis induction by pomegranate seed nano-emulsion in mice bearing solid Ehrlich carcinoma cells.
Mohamed HRH, Tulbah FSA, El-Ghor AA, Eissa SM. Mohamed HRH, et al. Sci Rep. 2023 Apr 4;13(1):5525. doi: 10.1038/s41598-023-32488-6. Sci Rep. 2023. PMID: 37016062 Free PMC article.
The In Vitro, Ex Vivo, and In Vivo Effect of Edible Oils: A Review on Cell Interactions.
Tsamesidis I, Kalogianni EP. Tsamesidis I, et al. Pharmaceutics. 2023 Mar 8;15(3):869. doi: 10.3390/pharmaceutics15030869. Pharmaceutics. 2023. PMID: 36986730 Free PMC article. Review.
Microencapsulated Pomegranate Modifies the Composition and Function of High-Density Lipoproteins (HDL) in New Zealand Rabbits.
Dorantes-Morales A, Estrada-Luna D, Bautista-Pérez R, Betanzos-Cabrera G, Luna-Luna M, Flores-Castillo C, Vargas-Alarcón G, Fragoso JM, Pérez-Méndez Ó, Carreón-Torres E. Dorantes-Morales A, et al. Molecules. 2020 Jul 21;25(14):3297. doi: 10.3390/molecules25143297. Molecules. 2020. PMID: 32708063 Free PMC article.

Effect of pomegranate seed oil on hyperlipidaemic subjects: a double-blind placebo-controlled clinical trial - PubMed (original) (raw)